Login to Your Account



Cephalon Plunks Down $225M Now, $300M Later for Gemin X

By Staff Reports


Tuesday, March 22, 2011
Gemin X Pharmaceuticals Inc., a firm that had been on the prowl for a partner after wowing Wall Street a couple of years ago with early stage data for small-cell lung cancer (SCLC) candidate obatoclax, was snatched up by Cephalon Inc. for $225 million up front.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription